Oral combination regimen Improves survival in ER-positive HER-2-negative breast cance

[News]

Patients with estrogen-receptor-positive HER-2-negative advanced breast cancer showed significantly improved progression-free survival when treated with an oral combination regimen that includes giredestrant, a novel, next-generation selective estrogen receptor degrader and full antagonist, compared to a standard combination approach.

More... (https://www.news-medical.net/news/20251018/Oral-combination-regimen-Improves-survival-in-ER-positive-HER-2-negative-breast-cancer.aspx)